However, comprehensive mutation testing of LZTR1, SMARCB1, and NF2 using DNA derived from blood and different tumour samples of the patient is the method of choice to distinguish between the two conditions (Castellanos et al. 2015; Smith et al. 2016). The gene discussed is SMARCB1; the disease is neoplasm.